ReviewTheranostics2015
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Review in Theranostics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 182 citations in OpenAlex.
- Injectable Thermosensitive Hydrogel Targeting STAT3 Reprograms Neutrophils to Amplify Anti-Tumor Immunity Post-Radiofrequency Ablation in HCC.Advanced healthcare materials · 2026Article
- Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment.Discover nano · 2026Review
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Free-floating patient-derived organotypic tumor spheroids (PDOTS) from non-small cell lung cancer (NSCLC) tumors: a versatile tool for personalized testing of chemotherapeutic drugs.Research in pharmaceutical sciences · 2025Article
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Targeting circulating tumor cell‒neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis.Journal of nanobiotechnology · 2025Review
- Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025Review
- Nucleic acid-based drugs for patients with solid tumours.Nature reviews. Clinical oncology · 2024Review
- Review
- Cell Membrane-Coated Nanotherapeutics for the Targeted Treatment of Acute and Chronic Colitis.Biomaterials research · 2024Article
- Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023Review
- Multifunctional nanostructures: Intelligent design to overcome biological barriers.Materials today. Bio · 2023Review
- Metal-Organic Framework-Based Nanomedicines for the Treatment of Intracellular Bacterial Infections.Pharmaceutics · 2023Review
- Theranostic applications of selenium nanomedicines against lung cancer.Journal of nanobiotechnology · 2023Review
- Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment.Cancers · 2022Review
- Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines.Pharmaceutics · 2022Article
- Functionalization of Nanoparticulate Drug Delivery Systems and Its Influence in Cancer Therapy.Pharmaceutics · 2022Review
- Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability of nanoparticles and macromolecules to passively accumulate in solid tumors and enhance therapeutic effects in comparison with conventional anticancer agents has resulted in the development of various multifunctional nanomedicines including liposomes, polymeric micelles, and magnetic nanoparticles. Further modifications of these nanoparticles have improved their characteristics in terms of tumor selectivity, circulation time in blood, enhanced uptake by cancer cells, and sensitivity to tumor microenvironment. These "smart" systems have enabled highly effective delivery of drugs, genes, shRNA, radioisotopes, and other therapeutic molecules. However, the resulting therapeutically relevant local concentrations of anticancer agents are often insufficient to cause tumor regression and complete elimination. Poor perfusion of inner regions of solid tumors as well as vascular barrier, high interstitial fluid pressure, and dense intercellular matrix are the main intratumoral barriers that impair drug delivery and impede uniform distribution of nanomedicines throughout a tumor. Here we review existing methods and approaches for improving tumoral uptake and distribution of nano-scaled therapeutic particles and macromolecules (i.e. nanomedicines). Briefly, these strategies include tuning physicochemical characteristics of nanomedicines, modulating physiological state of tumors with physical impacts or physiologically active agents, and active delivery of nanomedicines using cellular hitchhiking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.